SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):372P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Remediani, S.
Right arrow Articles by Massa, R.
PubMed
Right arrow Articles by Remediani, S.
Right arrow Articles by Massa, R.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Octreoscan (O) and cold somatostatin-analogue effectiveness in advanced androgen deprivation refractory prostate cancer (ADPRC)

Silvia Remediani1, Giuseppe De Vincentis1, Benedetta Criscuoli1, Stefano Gervasi1 and Rita Massa1

1 Radiological Sciences, University La Sapienza, Rome, Italy

1572

Objectives: To assess neuroendocrine features of ADRPC lesions and to relate O results with therapeutical effect of SA, we submitted 32 patients (pts) with ADPRC to O study. All pts had CT or Bone scan-proven bone, lymph-nodal or parenchimal metastases.

Methods: All pts were intravenously injected with 185 MBq of 111In-Pentetreotide. 4, 24 and 48 hours whole body and abdomen and pelvis O SPECT scan were obtained. SPECT were reconstructed by OSEM method (6 iterations). Performance status and bone pain, together with CgA and PSA serum levels were evaluated at baseline and after 3 months of SA therapy.

Results: CgA was elevated in 20/32 pts, whereas PSA in 26/32 pts. 13/32 pts had elevation of both markers and O scan resulted positive in all of them. O scan was positive in 25/32 pts, of whom 19 had CgA elevation and 21 PSA increase. 14/16 bone metastatic pts showed O uptake. O showed pathological findings in 6/7 liver metastatic pts, 3/5 lung metastatic pts, 1/3 pancreatic metastatic pts, 4/11 loco-regional lymph-nodes and 8/11 extra-regional lymph-nodes metastatic pts. Only a limited number of metastatic areas were characterized by SA uptake. Worth of note, the extension of O positive foci does not correlates with CgA levels. 4 pts experienced pain relief and/or performance status improvement after 3 months of SA therapy. Although O positive scans as well as serum markers levels alone were not predictor of SA responsiveness, all pts SA responders showed O positive scan and both high serum CgA and PSA levels.

Conclusions: O scan characterized prostate cancer metastatic lesions, expressing SA receptors. SA therapy responders presented association between O scan positivity and high serum levels of both PSA and CgA.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Remediani, S.
Right arrow Articles by Massa, R.
PubMed
Right arrow Articles by Remediani, S.
Right arrow Articles by Massa, R.